Ikena Oncology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

6 Mar 2025

IKNA

10-K: Ikena Oncology Announces Merger with Inmagene Biopharmaceuticals, Shifts Focus to Immunology

Ikena Oncology is set to merge with Inmagene Biopharmaceuticals, pivoting its focus to immunology and inflammatory diseases while legacy oncology programs may yield future value for Ikena investors.

12 Mar 2024

IKNA

Ikena Oncology, INC

10-K: Ikena Oncology's 10-K Filing: Focus on Targeted Therapies and Clinical Progress

Ikena Oncology's 10-K filing highlights its focus on targeted oncology therapies, particularly IK-930 and IK-595, and its progress in clinical trials.